Team:MIT/Treatment

From 2014.igem.org

(Difference between revisions)
Line 74: Line 74:
-
Suspendisse ornare turpis vitae quam ultrices, in interdum nunc fringilla. Donec volutpat leo justo, in vestibulum quam dictum vel. Fusce cursus elit non lacus rutrum porttitor. In enim odio, tincidunt ut facilisis ac, convallis non nisl. Nunc semper lorem nulla, et imperdiet mi faucibus ut. Mauris fermentum, ex in faucibus accumsan, lectus augue ornare tortor, id mattis massa felis et felis. Sed imperdiet dictum nibh at pellentesque. Donec et tincidunt orci, sit amet lobortis enim. Pellentesque facilisis semper eleifend. Cras varius ut nisl vel aliquet. Fusce mattis mollis ligula. Morbi elementum ac tortor at auctor. In scelerisque, mauris ac condimentum tristique, tortor sem porta dui, aliquet aliquam erat magna eget tortor.
+
• TRE: miRNA1
-
 
+
• TRE: miRNA2
-
Vestibulum non nibh mauris. Pellentesque nibh eros, semper eu erat ac, ornare lobortis orci. Etiam eget ultrices elit, nec faucibus erat. Suspendisse potenti. Fusce enim libero, luctus id condimentum eget, venenatis vitae augue. Aenean pellentesque tempor lectus, et ultricies augue varius sit amet. Sed imperdiet congue diam, quis fringilla magna porttitor at. Mauris pellentesque tincidunt nisi a lobortis. Sed eget fringilla dui, ut ultrices enim. Maecenas pulvinar dictum tristique. Suspendisse sodales condimentum egestas. Integer at felis nulla. Curabitur dignissim interdum justo non varius.
+
• TRE: miRNA3
-
 
+
• TRE: miRNA4
-
Fusce finibus lacus at tincidunt tempor. Pellentesque ullamcorper dictum blandit. Integer in porttitor nunc. Aliquam sodales ac velit id egestas. Phasellus mauris mauris, consectetur eget est sit amet, mollis rutrum eros. Etiam in risus id tellus dapibus lobortis posuere vitae risus. Sed vel justo sem. Proin eu tellus finibus, egestas nisl sed, aliquam tellus. Proin pretium lorem ultrices tincidunt gravida. Sed dolor urna, semper in fringilla a, rutrum sed quam. Sed pretium sapien enim, at dictum sapien dapibus a. Aenean a imperdiet turpis, eu lobortis eros. Praesent convallis, leo vitae consectetur vehicula, arcu odio tincidunt sem, eget venenatis mi purus vitae erat.
+
• Hef1a: BACE1
-
 
+
• Hef1a: eYFP-BACE1
-
Praesent non urna commodo, imperdiet ex quis, luctus diam. Pellentesque semper quam vel felis commodo semper. Sed vel elit sed urna tempus mollis vel vitae metus. Vivamus id tellus ligula. Duis eget auctor diam. Maecenas et libero at leo sodales congue. Pellentesque at dui quis arcu hendrerit dignissim vel quis dui. Curabitur finibus, ante vel tristique volutpat, lacus arcu varius purus, ut eleifend diam nunc sed est. Phasellus sed fringilla justo.
+
• Hef1a: BACE1-eYFP
-
 
+
• TRE: BACE2
-
Etiam venenatis rutrum lorem, dignissim dignissim odio egestas in. Duis tempor ultricies porttitor. In vitae hendrerit est. Sed id dolor nec ante maximus vestibulum nec vel velit. Curabitur pellentesque varius dui sed sagittis. Praesent vitae enim id arcu dictum imperdiet in a libero. Morbi sit amet risus quis lectus vestibulum hendrerit. Etiam non consectetur justo, quis tincidunt ex. Nam varius arcu at quam blandit elementum. Nam sit amet odio a ante tristique molestie nec a turpis. Phasellus mi lorem, venenatis feugiat dignissim quis, gravida vitae nibh. Aliquam sodales ex enim, fringilla finibus ipsum tincidunt in. Donec felis tortor, auctor sit amet luctus non, mattis vitae dui.
+
• TRE: eYFP-BACE2
 +
• TRE: BACE2-eYFP
 +
</td>
</td>

Revision as of 19:32, 17 October 2014

 


Image Map
Home Our Project Lab Work Outreach About Us Medals

Treatment Module

One liner description



Free JavaScripts provided
by The JavaScript Source

Outcome

Each of our three planned experiments for determining our effectiveness at re-regulating BACE1/BACE2 expression relied on successful transfection of our vectors into HEK293. Unfortunately, continual struggles with low transfection efficiency precluded us from performing any of our intended experiments. Analysis of our transfected HEK293 cultures with flow cytometry revealed very low numbers of live cells, suggesting that something had gone awry in the transfection protocol, in the quality of our vector constructs, or in our FACS preparation process. In any case, the lack of usable HEK293 meant we had no samples on which to perform any of our three intended experiments. This is an issue we hope to resolve soon so that we can make meaningful conclusions about the success of the Treatment module.

Experiments


The Treatment module is actuated upon release of transcription factor rtTA, initiating a two-part response. The first of these two responses is transcriptional up-regulation of an exogenously delivered vector expressing the Bace2 protease. Bace2 recognizes cleavage sites within Aβ and so is thought to be a potentially effective therapeutic for degrading plaques. The second response activated by the release of rtTA is transcriptional expression of a miRNA targeted specifically to BACE1. We constructed four independent miRNA-generating vectors, each targeted to a different region of the BACE1 mRNA sequence. The benefit of having multiple unique miRNA’s is the ability to test the relative efficacy of each at down-regulating BACE1 translational expression. Predicting an effective miRNA depends on a variety of factors ranging from the sequence of bases that flank the guide region, to the degree of complementarity between the miRNA and its target, to the region of the target that the miRNA binds. To test our miRNA’s effectiveness at down-regulating BACE1 expression we transfected separate HEK293 cultures with either (1) BACE1 under constitutive expression by the Hef1a promoter or (2) with BACE1 under constitutive expression by the Hef1a promoter and with a miRNA-generating vector inducibly regulated by the TRE promoter. We performed these transfections in duplicate—once with native BACE1, and then once with eYFP-tagged BACE1. There were two variants of this eYFP-tagged BACE1 construct—one with eYFP linked to the N-terminus of Bace1 and another with eYFP on the C-terminus. We created these two variants after considering the possibility that linking eYFP to either terminus of Bace1 might interfere with the peptide’s native structure or function. After transfection and Doxycycline-induction of our miRNA-generating vectors, we used flow cytometry to verify that the miRNA-generating vectors were being expressed. Proper splicing of the mature miRNA out of the expression vector leaves an intact mKate coding sequence in the vector, so emission of red fluorescence from our transfected HEK293 indicates proper miRNA processing. Following confirmation of successful miRNA expression, we planned three experiments to assay the change in BACE1 expression by miRNA’s. The first experiment was based on Anaspec’s SensoLyte 520 β-Secretase Assay Kit. This commercial kit uses a FRET-based technique wherein biological samples are mixed with a proprietary solution containing a BACE1 mimic substrate. One terminal of this mimic substrate is conjugated to a fluorophore and the other terminal is conjugated to a fluorescence quencher. So proteolytic Bace1 activity causes cleavage of the proprietary substrate, which increases fluorescence due to separation of the fluorophore from the quencher. Relative Bace1 activity in biological samples can be assayed by measuring the intensity of the fluorophore emission and comparing to a standard curve. The second planned experiment involved the previously mentioned eYFP-tagged Bace1 construct. Comparison of yellow fluorescence in miRNA-transfected versus miRNA-untransfected HEK293 would offer evidence as to whether BACE1 expression increases or decreases under the regulation of our miRNA’s. Furthermore, microscopy would allow us to visualize where Bace1 localizes in the cell. Our third intended experiment was RT-PCR. We planned to isolate bulk RNA from the transfected HEK293, perform cDNA synthesis on the isolated RNA, and then use quantitative RT-PCR to determine the relative amount of Bace1 mRNA in miRNA-transfected versus miRNA-untransfected HEK293 to determine the efficacy of our miRNA’s in targeting BACE1 mRNA for degradation. Our experiments to test our effectiveness at inducibly up-regulating BACE2 expression relied essentially on the same assays for BACE1: an Anaspec FRET assay; measurement of fluorescence from the YFP-tagged transfections; and RT-PCR. The one important difference between the BACE1 and BACE2 experiments was only that the BACE2 experiment required a simpler initial transfection. We transfected two cultures of HEK293 with either (1) a vector inducibly expressing BACE2 under control of the TRE promoter or (2) with a vector inducibly expressing BACE2 under control of a TRE promoter and with a vector constitutively expressing the rtTA transcription factor. So by comparing the amount of BACE2 expression in the induced versus un-induced transfection samples, we could determine our effectiveness at up-regulating BACE2 expression.

Parts

• TRE: miRNA1 • TRE: miRNA2 • TRE: miRNA3 • TRE: miRNA4 • Hef1a: BACE1 • Hef1a: eYFP-BACE1 • Hef1a: BACE1-eYFP • TRE: BACE2 • TRE: eYFP-BACE2 • TRE: BACE2-eYFP

Retrieved from "http://2014.igem.org/Team:MIT/Treatment"